The changes set to disrupt biopharma manufacturing in 2020

We speak to Elanco, Bayer, Janssen and Ipsen to find out what they think will be the biggest changes in the industry over the next year

Add bookmark

Pharma IQ

The biopharma manufacturing environment is dynamic, facing a number of pressures which will undoubtedly lead to significant change. To find out what the most impactful changes will be in the next 12 months, we spoke to leading industry experts to hear their thoughts. 

Roger Cassidy, Managing Director at Tamesis Pharma

"I think it might be the regulatory environment. I think we’re going to see some big changes and  that could be a positive thing. We’ve seen over the last few years, faster regulatory approvals for certain drugs, we’ve also seen the fast tracking of orphan drugs and other areas. It could be a positive thing, but for those who aren’t properly prepared it could slow things down because of this more extensive regulatory approval you might need to go through."

RELATED: Find out how Augmented Reality will change the biopharma facility of the future in this webinar 


Diogo Chaves, Director of Global Procurement and External Manufacturing at Elanco Animal Health

"I think the CMO relationship with pharma companies is still at a quite early stage of maturity. I think this has been evolving tremendously but there is a lot more room for development. I think everybody is still playing very tactical, playing very much into today’s need of overcapacity or immediate needs from a quality perspective. But the future will hold a lot bigger relationships that are more strategic to understand each other and development capabilities. How do we develop products together? How do we access new markets and dominate specific fields together in partnership? That, in my opinion, will be the future of these relationships."


Kyriakos Berberidis, Director Supply Chain, Partnerships and  External Supply at Janssen

"Well, most of the big pharma industry is seeking partners with specialized capabilities and technologies. What I foresee is that there will be a lot of opportunities in the next 24 months especially for high potent and biotech products, antibiotics as well. This is what we see as a growing market in the pharmaceutical industry which also involves local manufacturing opportunities."


Luiz Barberini, Head Operations Manager, External Manufacturing in Latin America at Bayer

"I really think that we will have no changes for the next 12 months. This will take longer. And we will be focused on big data and information. We have a long way to go with information and information exchange, so I can better prepare myself and have better plans.  If I know the requirements from my CMOs and he knows me and my needs through our data exchange, we can grow together. The extreme situation that people talk a lot about is Industry 4.0. This means a full integrated process between the industry, it will be a revolution, but not in the next 12 months or even probably in the next few years. I think it will take a little longer. We don’t even mange the full processes within our companies so how can we do that with integrated companies?"

READ MORE: In this analysis, we discuss how Industry 4.0 technology could solve some of the biggest risks in single use manufacturing facilities


Felix Faupel, Associate Director of Contract Manufacturing at Acino

"To be honest, I don’t think there will be a big change in the next 12 months because our industry is rather slow moving. What I see, of course, is that digitalization in our industry is a big topic. You start working with a lot of data analysts within the CMO industry. You look more into how you can make data more accessible to our customer? How can you integrate customers into your systems? How can you work better together, for example on share-points? How can you make transfer projects easier?"


Mark Clinton, Director External Manufacturing at Ipsen

"The biggest change…There’s this phrase; big data. But what does it mean to the pharmaceutical industry and how do we manage that and use it to our advantage to get some leverage with our competition and with our CMOs."


Did you read our Big Book of Biotech? If not, download your copy now. With insights from Novartis, Merck, Rockwell and GSK, you can expect a deep dive on CRISPR delviery challenges, stem cell characterization maturity, gene editing and the supply chain impact of the biologics boom.